OU Xiang
Department of Endocrinology, the First Hospital of Changsha, Changsha, Hunan 410005, ChinaCHEN Ling-Yan
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaZHOU Zhi-Jiao
Department of Pathology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, ChinaXIA Xiao-Dan
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaGONG Duo
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaZHAO Zhen-Wang
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaWANG Si-Qi
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaZHANG Qiang
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, ChinaTANG Chao-Ke
Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, China1.Department of Endocrinology, the First Hospital of Changsha, Changsha, Hunan 410005, China;2.Institute of Cardiovascular Diseases, University of South China & Key Laboratory for Atherosclerology of Hunan Province & Medical Research Center, University of South China & Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, Hunan 421001, China;3.Department of Pathology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China)
R363
OU Xiang, CHEN Ling-Yan, ZHOU Zhi-Jiao, XIA Xiao-Dan, GONG Duo, ZHAO Zhen-Wang, WANG Si-Qi, ZHANG Qiang, TANG Chao-Ke. Angiopoietin-1 mediates ABCA1, ABCG1 expression and cholesterol efflux through LXRα pathway in THP-1 derived macrophages[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2017,25(11):1081-1087.
Copy